...
首页> 外文期刊>Coordination chemistry reviews >Recent advances in metallodrug-like molecules targeting non-coding RNAs in cancer chemotherapy
【24h】

Recent advances in metallodrug-like molecules targeting non-coding RNAs in cancer chemotherapy

机译:Metallodrug样分子的最新进展靶向非编码RNA在癌症化疗中

获取原文
获取原文并翻译 | 示例
           

摘要

New drug discovery strategies are emerging at a rapid pace to combat the threat of mortality caused by various chronic diseases viz., HIV-AIDS, respiratory infections and cancers. The therapeutic intervention is necessary for synthesizing robust pharmaceuticals and to unlock the mechanistic aspects of pathogens involved in diseases. These therapeutic regimes have diverted from traditional target DNA to new exciting novel targets viz., structured proteins, enzyme receptors, ribonucleoprotein (RNP) particles and non coding RNAs. RNA has much attractive prospectus as an antitumor therapeutic target being involved in many essential biochemical, genetic and epigenetic functions of the cell. The structural flexibility of RNA both in secondary and tertiary structure owing to which selective binding based on structures rather than sequence is possible while RNP particles have exhibited reasonable therapeutic success in the antibacterial area. RNA was much ignored and underexploited target due to difficulty in characterisation and unavailability of sensitive biophysical/biochemical techniques to study its intricate threedimensional folds. However, recent developments have provided valuable insights into RNA targets, and its binding abilities, the small molecule RNA-based drugs have emerged, and many antitumor lead compounds targeted to RNA including organic dyes, intercalative cations, aminoglycoside antibiotics and inorganic metal complexes were isolated, and some of them have reached clinical trial phases in drug discovery. Interestingly, the development of high-resolution RNA structural analysis, using both X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy has clearly made a profound impact in this area. In the present review, we are looking at more naive options of modulating drug discovery strategies involving metallodrugs derived from transition metal ions which are targeted to ncRNAs. Metal complexes exhibit diversity in size and structure beyond the geometries of carbon, possess photo physical and electrochemical properties and therefore are considered as an important class of structure selective binding agents for nucleic acids. Herein, we describe innovative rational designs of metallodrugs targeted to non-coding RNA structures and their future biological prospectus in drug design. (C) 2019 Elsevier B.V. All rights reserved.
机译:新的药物发现策略正在迅速推出,以对抗各种慢性病疾病,艾滋病毒,呼吸道感染和癌症造成的死亡威胁。治疗干预是合成鲁棒药物的必要条件,并解锁患有疾病所涉及的病原体的机械方面。这些治疗方法已从传统靶DNA转移到新的令人兴奋的新靶靶菌,结构蛋白质,酶受体,核糖核蛋白(RNP)颗粒和非编码RNA。 RNA具有与抗肿瘤治疗目标有吸引力的招股章程参与细胞的许多必需生化,遗传和表观遗传功能。次级和三级结构中RNA的结构柔韧性由于基于结构而不是序列的选择性结合,而RNP颗粒在抗菌区域中表现出合理的治疗成功。由于难以研究其复杂的三维折叠的敏感性和生物化学技术的表征和不可用的困难,RNA非常忽略和曝光不足的目标。然而,最近的发展已经为RNA靶标提供了有价值的见解,并且其结合能力是出现的小分子RNA的药物,以及许多靶向包括有机染料,插入阳离子,氨基糖苷抗生素和无机金属配合物的RNA的许多抗肿瘤铅化合物其中一些人在药物发现中达到了临床试验阶段。有趣的是,高分辨率RNA结构分析的发展,使用X射线晶体学和核磁共振(NMR)光谱在该地区显然产生了深刻的影响。在本综述中,我们正在寻找更多的天真选择调节涉及从靶向NCRNA的过渡金属离子的Metallodrugs的药物发现策略。金属配合物在碳几何形状的大小和结构上表现出多样性,具有照片物理和电化学性质,因此被认为是核酸的重要组织选择性结合剂。在此,我们描述了靶向非编码RNA结构的Metallodrugs的创新理性设计及其在药物设计中的未来生物学招生。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号